Title:Can Probiotics Supplementation Improve Glycemic and Renal Status in
Diabetic Nephropathy? A Systematic Review and Meta-Analysis of Clinical
Trials
Volume: 22
Issue: 1
Author(s): Mohammad Javad Tarrahi , Iman Namjoo, Mohammad Borzoo-Isfahani, Hadiseh Ebdali and Amir Reza Moravejolahkami*
Affiliation:
- Department of Clinical Nutrition, School of Nutrition & Food Science, Isfahan University of Medical Sciences, Isfahan,Iran
Keywords:
Probiotics, clinical laboratory techniques, diabetic nephropathies, meta-analysis, systematic review, clinical trials.
Abstract: Background & Aim: This meta-analysis was performed to quantify the effects of probiotics
on renal and glycemic biomarkers among patients with Diabetic Nephropathy (DN).
Methods: Electronic databases were searched on May 10, 2020. All trials that investigated the effect
of probiotics on serum glycemic markers (Fasting Plasma Glucose [FPG], Hemoglobin A1C,
Insulin, Homeostatic Model Assessment-Insulin Resistance [HOMA-IR], and Quantitative Insulin
Sensitivity Check Index [QUICKI]), and renal status markers (Creatinine [Cr], Blood Urea Nitrogen
[BUN], and Glomerular Filtration Rate [GFR]) were included.
Results: Seven trials that included 340 patients were identified for analysis. The results indicated
that probiotics significantly reduced FPG (WMD= -19.08 mg/dl; 95% CI= -32.16, -5.99; P=0.004),
HOMA-IR (WMD= -1.88; 95% CI= -3.63, -0.12; P=0.036), and Cr (WMD= -0.18 mg/dl; 95% CI=
-0.26, -0.09; P<0.001) levels in DN patients; however, there was no statistically significant change
in Hemoglobin A1C, Insulin, QUICKI, BUN, and GFR.
Conclusion: This meta-analysis supports the potential use of probiotics in the improvement of
some glycemic and renal biomarkers in patients with DN.